Amylyx Pharmaceuticals, Inc. AMLX
As ofNov 20, 2026, 2:09 PM EST
- YTD
- +117.38%
- 1 year
- +93.51%
5D -4.22 (-13.68%)
- Market cap
- 3.38B
- EPS (ttm)
- -1.43
- Shares out
- 128.56M
- Forward P/E
- -22.22
- YTD return
- +117.38%
- 1-year return
- +93.51%
- 50-day average
- 29.28
- 200-day average
- 20.99
- Enterprise value
- 2.66B
- Price / book
- 4.47
- Volume
- 633.07K
- Avg volume
- 1.58M
- Open
- 25.64
- Previous close
- 26.20
- Day's range
- 25.52 – 26.40
- 52-week range
- 10.83 – 41.14
- Beta
- -0.08
- Analysts
- Strong Buy
- Price target
- 43.00 (+63.7%)
- Earnings date
- Mar 2, 2027
Key statistics
- Free cash flow
- -80.52M
- Total cash
- 768.13M
- Total debt
- 4.94M
- Return on equity
- -30.06%
- Short % of float
- 12.41%
Fundamental scorecard
4 of 25 checks passed on AMLX’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 25.00
- Target (mean)
- 43.00
- Target (high)
- 57.00
- Strong buy0
- Buy10
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 2, 2027
Expected Mar 2, 2027. Consensus EPS estimate -0.37433.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 2, 2027 | Dec 30, 2026 | -0.36 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -0.38099 | -0.38 | 0.00 | +0.26% |
| Aug 6, 2026 | Jun 30, 2026 | -0.3609 | -0.39 | -0.03 | -8.06% |
| May 7, 2026 | Mar 31, 2026 | -0.34 | -0.37 | -0.03 | -8.82% |
| Mar 3, 2026 | Dec 31, 2025 | -0.31 | -0.30 | +0.01 | +3.23% |
| Nov 6, 2025 | Sep 30, 2025 | -0.43 | -0.37 | +0.06 | +13.95% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | Mizuho | main | Outperform | Outperform |
| Oct 15, 2026 | Citigroup | main | Buy | Buy |
| Aug 27, 2026 | Guggenheim | main | Buy | Buy |
| Aug 19, 2026 | Mizuho | main | Outperform | Outperform |
| Aug 19, 2026 | Guggenheim | main | Buy | Buy |
| Aug 19, 2026 | Baird | main | Outperform | Outperform |
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- amylyx.com
News
HC Wainwright & Co. Reiterates Buy on Amylyx Pharmaceuticals, Maintains $55 Price Target
Reported Saturday, Avexitide Meets Phase 3 LUCIDITY Primary Endpoint In Post-Bariatric Hypoglycemia, Cutting Level 2/3 Events 0.55 Per Week Versus 1.24 For Placebo, With No Treatment-Related Serious Adverse Events
Amylyx Pharmaceuticals, Inc. (AMLX) Discusses LUCIDITY Results and Avexitide Potential in Post-Bariatric Hypoglycemia Transcript
Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $39
Amylyx Pharma Q3 EPS $(0.38), Inline
Your note
Sign in to keep a note on AMLX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEDROSIAN CAMILLE L | Officer | Sale | Sep 9, 2026 | 278,064 |
| COHEN JOSHUA BARRY | Chief Executive Officer | Sale | Nov 8, 2026 | 3,513,120 |
| FIRESTONE KAREN M. | Director | Conversion of Exercise of derivative security | Aug 30, 2026 | 116,900 |
| FRATES JAMES MATTHEW | Chief Financial Officer | Sale | Nov 9, 2026 | 400,156 |
| KLEE JUSTIN B | Chief Executive Officer | Sale | Nov 8, 2026 | 3,513,060 |
| MAZZARIELLO GINA | Officer | Sale | Sep 9, 2026 | 190,838 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 15.51% | 19,945,501 | 522.57M | Sep 29, 2026 |
| Perceptive Advisors Llc | 8.22% | 10,573,735 | 277.03M | Sep 29, 2026 |
| Blackrock Inc. | 8.06% | 10,368,007 | 271.64M | Sep 29, 2026 |
| TCG Crossover Management, LLC | 4.86% | 6,243,812 | 163.59M | Sep 29, 2026 |
| Driehaus Capital Management, LLC | 4.22% | 5,428,489 | 142.23M | Sep 29, 2026 |
| Janus Henderson Group Ltd. | 4.20% | 5,400,720 | 141.50M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.45% | 3,154,723 | 82.65M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.10% | 2,694,093 | 70.59M | Sep 29, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 1.89% | 2,433,200 | 63.75M | Sep 29, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.65% | 2,115,961 | 55.44M | Aug 30, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 1.32% | 1,695,959 | 44.43M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.25% | 1,601,402 | 41.96M | Sep 29, 2026 |
